Matrix Metalloproteinase-9/Neutrophil Gelatinase-Associated Lipocalin Complex Activity in Human Glioma Samples Predicts Tumor Presence and Clinical Prognosis. (18th November 2015)

• Record Type: Journal Article
• Authors: Liu, Ming-Fa; Hu, Yong-Yang; Jin, Tao; Xu, Ke; Wang, Shao-Hong; Du, Guang-Zhou; Wu, Bing-Li; Li, Li-Yan; Xu, Li-Yan; Li, En-Min; Xu, Hai-Xiong
• Other Names: Pichler Robert Academic Editor.
• Is Part Of: Disease markers. Volume 2015(2015)
• Publication Date: 2015-11-18
• Subjects: Diagnosis -- Periodicals; Biochemical markers -- Periodicals; Pathology -- Periodicals; 616
• DOI: 10.1155/2015/138974
• Languages: English
• ISSNs: 0278-0240

Abstract

Abstract : Matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin (MMP-9/NGAL) complex activity is elevated in brain tumors and may serve as a molecular marker for brain tumors. However, the relationship between MMP-9/NGAL activity in brain tumors and patient prognosis and treatment response remains unclear. Here, we compared the clinical characteristics of glioma patients with the MMP-9/NGAL activity measured in their respective tumor and urine samples. Using gelatin zymography assays, we found that MMP-9/NGAL activity was significantly increased in tumor tissues (TT) and preoperative urine samples (Preop-1d urine). Activity was reduced by seven days after surgery (Postop-1w urine) and elevated again in cases of tumor recurrence. The MMP-9/NGAL status correlated well with MRI-based tumor assessments. These findings suggest that MMP-9/NGAL activity could be a novel marker to detect gliomas and predict the clinical outcome of patients.